113. 筋ジストロフィー [臨床試験数:567,薬物数:442(DrugBank:93),標的遺伝子数:55,標的パスウェイ数:151

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03777319December 5, 201810/12/2018Spironolactone Versus Prednisolone in DMDA Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMDMuscular Dystrophy, DuchenneDrug: Spironolactone;Drug: PrednisoloneKevin FlaniganMuscular Dystrophy AssociationRecruiting4 Years7 YearsMale24Phase 1United States
2NCT02354352March 20, 201527/1/2015Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyTherapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: Eplerenone;Drug: SpironolactoneOhio State UniversityUniversity of California, Los Angeles;University of Utah;University of Colorado, Denver;University of Kansas Medical Center;Vanderbilt University Medical CenterCompleted7 YearsN/AMale52Phase 3United States